Hims Reports $33M Loss Amid Shift to GLP-1 Weight Loss Drugs
Hims & Hers Health Inc. (Hims) incurred a $33 million non-cash impairment charge in Q2 2024 due to its strategic pivot toward GLP-1 weight loss medica...
Xeber.world
GLP-1
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Boehringer’s Obesity Drug Achieves 16.6% Weight Loss in Trial; Further Data Pending
Boehringer’s investigational obesity drug demonstrated a 16.6% weight loss in a clinical trial, outperforming many existing treatments. However, addit...
Gwyneth Paltrow’s Peptide Confusion Highlights the Wellness Industry’s Hype
Gwyneth Paltrow’s recent comments about peptides reveal a gap between celebrity-endorsed wellness trends and scientific understanding. From subway ads...
FDA Approves Higher Dose Wegovy Injection for Enhanced Weight Loss Results
The FDA has approved a 7.2 mg weekly dose of Wegovy, a GLP-1 medication, for weight loss. Clinical trials show this higher dose can lead to 25% more w...